Charles N. York II Sells 4,106 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Key Points

• CFO Charles York II of Day One Biopharmaceuticals sold 4,106 shares at an average price of $6.77, reducing his ownership by 1.46%.
• Following the latest earnings report, the company had a revenue of $33.91 million, missing the consensus estimate of $35.55 million, with expected -0.72 EPS for the current fiscal year.
• Equity analysts remain optimistic, with several setting price targets of $25 for the stock and an average rating of 'Buy'.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CFO Charles N. York II sold 4,106 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $6.77, for a total transaction of $27,797.62. Following the completion of the transaction, the chief financial officer owned 278,000 shares in the company, valued at approximately $1,882,060. This represents a 1.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Day One Biopharmaceuticals Price Performance

Day One Biopharmaceuticals stock traded up $0.22 during midday trading on Friday, reaching $7.20. 1,648,230 shares of the company traded hands, compared to its average volume of 2,114,697. The firm has a market capitalization of $737.50 million, a price-to-earnings ratio of -7.58 and a beta of -1.26. The business has a 50 day moving average of $6.63 and a two-hundred day moving average of $7.57. Day One Biopharmaceuticals, Inc. has a 12 month low of $5.64 and a 12 month high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The company had revenue of $33.91 million for the quarter, compared to the consensus estimate of $35.55 million. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative return on equity of 19.01%. As a group, equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Wedbush reaffirmed an "outperform" rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC reduced their target price on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Piper Sandler assumed coverage on shares of Day One Biopharmaceuticals in a report on Monday, August 18th. They set an "overweight" rating and a $25.00 target price for the company. Finally, HC Wainwright reduced their target price on shares of Day One Biopharmaceuticals from $36.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $25.29.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth $27,000. Ameritas Investment Partners Inc. increased its stake in shares of Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company's stock worth $48,000 after purchasing an additional 2,264 shares in the last quarter. Entropy Technologies LP purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter worth $67,000. Prudential Financial Inc. purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter worth $69,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter worth $76,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.